Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal by Brás, JM et al.
Complete screening for glucocerebrosidase mutations in
parkinson disease patients from portugal
Jose Bras1,2, Coro Paisan-Ruiz1, Rita Guerreiro1,2, Maria Helena Ribeiro2, Ana
Morgadinho3, Cristina Januario3, Ellen Sidransky4, Catarina Oliveira2, and Andrew
Singleton1,*
1Laboratory of Neurogenetics, National Institutes on Aging, National Institutes of Health, Bethesda,
Maryland, USA
2Center for Neurosciences and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra,
Portugal
3Neurology Service, Coimbra University Hospital, Coimbra, Portugal
4Medical Genetics Branch, National Human Genome Research Institute, National Institutes of
Health, Bethesda, Maryland, USA
Abstract
Mutations in the gene encoding beta-glucocerebrosidase, a lysosomal degrading enzyme, have
recently been associated with the development of Parkinson disease.
Here we report the results found in a cohort of Portuguese Parkinson disease patients and healthy
age-matched controls for mutations in the aforementioned gene. This screening was accomplished
by sequencing the complete open-reading frame, as well as intron/exon boundaries, of the
glucocerebrosidase gene, in a total of 230 patients and 430 controls.
We have found an increased number of Parkinson disease patients presenting mutations in GBA
when compared to controls.
These results, together with recent literature, clearly suggest a role of glucocerebrosidase in the
development of Parkinson disease.
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Introduction
Mutations and complex rearrangements in the gene encoding β-glucocerebrosidase (GBA)
cause Gaucher disease (GD), an autosomal recessive lysosomal storage disorder often
categorized in three main sub-types: nonneuronopathic type 1, acute neuronopathic type 2 and
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subacute neuronopathic type 3. The clinical features in patients with GD vary greatly, ranging
from asymptomatic octogenarians to severely affected infants with hepatosplenomegaly,
developmental regression and growth arrest. The symptoms encountered in GD do not typically
overlap significantly with those seen in patients with Parkinson disease (PD). However, there
have been reports describing rare patients with GD who develop manifestations of PD. This
prompted researchers to explore the prevalence of mutations in GBA among subjects with PD;
the startling association between GBA mutations and PD in brain bank samples (Lwin et al.
2004) led others to assess Jewish and non-Jewish populations (Aharon-Peretz et al. 2004;
Ziegler et al. 2007). Several replication studies have been published with positive and negative
associations; the relative rarity of mutations and the complexity of the genomic region where
GBA is associated resulted in studies that were underpowered or were focused only on specific
mutations.
Materials and Methods
Here we report the results of complete sequence analysis of GBA in a series of 230 Portuguese
patients with PD, collected sequentially at the Coimbra University Hospital in Portugal and in
430 healthy age-matched controls. All subjects were Caucasian and of apparent Portuguese
ancestry. Diagnosis was made in accordance with the UK Brain Bank criteria. Family history
was considered positive if at least one family member presented with PD. The entire coding
region and the exon/intron boundaries of GBA gene were sequenced in all subjects (details
available upon request). To exclude false positives due to co-amplification of the pseudogene,
all mutations were confirmed by sequencing bands excised from an agarose gel, following PCR
amplification of a fresh DNA aliquot.
Results
The PD group yielded 14 carriers of previously described pathogenic GBA mutations (N370S,
N396T, D409H and L444P), all heterozygous, while the control group yielded 3 N370S
carriers, also heterozygotes (Table 1). Two variants, E326K and T369M, previously described
as non-pathogenic polymorphisms, were identified in both patients and controls. In addition,
2 novel variants and one previously described variant of unknown significance were identified
(p.K13R; p.R41L and p.E427K) (Rozenberg et al. 2006).
Discussion
We found a frequency of 6.1% (14/230) known pathogenic mutations in the PD series and
0.7% (3/430) in the control group. These results represent a significantly higher frequency of
mutations in GBA in PD patients when compared to controls (p<0.001; OR=9.2; 95% CI
2.6-32.4). Of note, the control group shows no mutations associated with severe GD; while
they exist in the PD group – 4/14 patients with L444P or D409H. If we consider the variants
of unknown pathogenicity (p.K13R; p.R41L and p.E427K) as potentially causative, this
association still remains (p<0.001; OR=4.9; 95% CI 1.9-12.9).
The most common mutation identified was N370S, the most frequently identified pathogenic
mutation in Ashkenazi Jewish as well as Portuguese patients with GD. Based on screening of
2000 random cord blood samples in Portugal, the carrier frequency of this mutation is estimated
to be 0.0043 in this population (Lacerda et al. 1994). This mutation is believed to account for
63% of the mutant alleles in Portuguese patients with GD. Although the N370S mutation was
three times more frequent in the PD group when compared to controls, we did not have
sufficient power to identify a statistically significant association analyzing this mutation alone
(P=0.079; OR 3.3; 95% CI 0.75-13.4). Mutation N396T, encountered in 5 subjects in this study,
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was first identified in Portugal and has proven to be a relatively common mutation in this
population (Amaral et al. 2000).
This study substantiates the need to sequence GBA in non-Ashkenazi cohorts in order to
accurately determine the frequency of mutations in this gene. Had we screened only for
common Gaucher mutations, we would have missed 43% of the mutant alleles in this
population.
The association of GBA mutations with PD in the Portuguese population is particularly
interesting when it is noted that the mutation driving this association is one associated with
Jewish ancestry, and that another PD causing mutation, p.G2019S of LRRK2, underlying
∼6% of Portuguese PD cases (Bras et al. 2005), is also associated with Ashkenazi Jewish
ancestry; these data clearly illustrate the contribution of Jewish ancestry to the modern
Portuguese population.
In summary using a cohort with a different and defined ethnicity, we demonstrate that GBA
mutations are significantly more common in patients with PD than in neurologically normal
controls. These findings illustrate that the identification of such an association requires large
sample series, even when using populations where GBA mutations are enriched; thus detection
of such an association in populations with non-Ashkenazi ancestry is likely to require thousands
of samples.
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